| 标题： | 类风湿关节炎超药品说明书用药中国专家共识（2022版） |
| title： | Chinese Expert Consensus on off-label Use of rheumatoid arthritis (2022 version) |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 治疗 |
| field： | Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 各级临床医生（风湿病、药学和其他相关领域） |
| Guide users： | Clinical physicians at all levels (rheumatology, pharmacy, and other relevant fields) |
| 证据分级方法： | 检索国外药品说明书，MICROMEDEX数据库，临床指南、共识、临床研究等方面相关文献，收集类风湿关节炎超药品说明书用药相关证据, 参 照 Micromedex 的 Thomson 分级系统标准，对有效性等级、推荐等级及证据等级三方面进行评价。组织风湿病学专家、药学专家，结合循证医学证据，通过德尔菲法评估优化达成共识。 |
| Evidence grading method： | Relevant evidence on drug label, guidelines, consensuses, MICROMEDEX database, clinical studies are collected and evaluated. We evaluate the effectiveness grade, recommendation grade and evidence grade by referring to the Thomson classification system standard of Micromedex.In combination with evidence, experts of rheumatology, pharmacy are inquiried,and reach a consensus through the evaluation and optimization of the Delphi method. |
| 制定单位： | 中山大学孙逸仙纪念医院 |
| Formulating unit： | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University |
| 注册时间： | 2022-10-16 |
| Registration time： | |
| 注册编号： | PREPARE-2022CN654 |
| Registration number： | |
| 指南制订的目的： | 近年，新的类风湿关节炎治疗药物不断上市，同时新的循证医学证据及不断更新的国内外指南提示更多药物能用于备孕期、妊娠期、哺乳期等特殊时期类风湿关节炎患者，但药品说明书的更新却相对滞后。因此，有必要对类风湿关节炎超药品说明书用法形成专家共识，旨在为临床医生超说明书用药治疗类风湿关节炎提供依据的同时，进一步规范类风湿关节炎超药品说明书用药的临床实践。 |
| Purpose of the guideline： | In recent years, new drugs for the treatment of rheumatoid arthritis continue to be marketed, and new evidence-based medical evidence and updated domestic and foreign guidelines suggest that more drugs can be used for patients with rheumatoid arthritis in special periods such as pregnancy, pregnancy and lactation, but the update of drug instructions is relatively lagging behind.Therefore, it is necessary to form an expert consensus on the off-label use of rheumatoid arthritis, in order to provide a basis for clinicians to use off-label drugs in the treatment of rheumatoid arthritis, and to further standardize the clinical practice of off-label use of rheumatoid arthritis. |
